Promising Targets for the Treatment of Neurodegenerative Diseases

Clinical Pharmacology and Therapeutics

Volumn 98, Issue 5, 2015, Pages 492-501

  Budd Haeberlein, S L ^a   Harris, T J R ^a  

^a BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID; APOLIPOPROTEIN E; COPPER ZINC SUPEROXIDE DISMUTASE; FUSED IN SARCOMA PROTEIN; GLUCOSYLCERAMIDASE; PHOSPHOTRANSFERASE; PROGRANULIN; PTEN INDUCED KINASE 1; TANK BINDING KINASE 1; TAU PROTEIN; UNCLASSIFIED DRUG; VALOSIN CONTAINING PROTEIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; DEGENERATIVE DISEASE; FRONTOTEMPORAL DEMENTIA; GENETICS; HUMAN; HUNTINGTON CHOREA; INFLAMMATION; OPEN READING FRAME; PARKINSON DISEASE; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; DRUG DELIVERY SYSTEM; GENE TARGETING; GENE THERAPY; NEURODEGENERATIVE DISEASES; TREATMENT OUTCOME; TRENDS;

DRUG DELIVERY SYSTEMS; GENE TARGETING; GENETIC THERAPY; HUMANS; NEURODEGENERATIVE DISEASES; TREATMENT OUTCOME;

EID: 84957790859     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.195     Document Type: Article

References (75)

1. Braak, H. & Braak, E. Cortical and subcortical argyrophilic grains characterize a disease associated with adult onset dementia. Neuropathol. Appl. Neurobiol. 15, 13-26 (1989).
2. Jonsson, T. et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488, 96-99 (2012).
3. Lannfelt, L., Relkin, N.R. & Siemers, E.R. Amyloid-b-directed immunotherapy for Alzheimer's disease. J. Intern. Med. 275, 284-295 (2014).
4. Golde, T.E., Koo, E.H., Felsenstein, K.M., Osborne, B.A. & Miele, L. γ-Secretase inhibitors and modulators. Biochim. Biophys. Acta. 1828, 2898-2907 (2013).
5. Vassar, R. et al. Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects. J. Neurochem. 130, 4-28 (2014).
6. Hutton, M. et al. Association of missense and 5″-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393, 702-705 (1998).
7. Martin, L. et al. Tauproteinkinases: involvement in Alzheimer's disease. Ageing Res. Rev. 12, 289-309 (2013).
8. Frost, B., Jacks, R.L. & Diamond, M.I. Propagation of tau misfolding from the outside to the inside of a cell. J. Biol. Chem. 284, 12845-12852 (2009).
9. Iba, M., Guo, J.L., McBride, J.D., Zhang, B., Trojanowski, J.Q. & Lee, V.M. Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy. J. Neurosci. 33, 1024-1037 (2013).
10. Chai, X., Dage, J.L. & Citron, M. Constitutive secretion of tau protein by an unconventional mechanism. Neurobiol. Dis. 48, 356-366 (2012).
11. Yanamandra, K. et al. Anti-tau antibody reduces insoluble tau and decreases brain atrophy. Ann. Clin. Transl. Neurol. 2, 278-288 (2015).
12. Sankaranarayanan, S. et al. Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models. PLoS One 10, e0125614 (2015).
13. Saykin, A.J. et al. Genetic studies in quantitative MCI and AD phenotypes in ADNI: progress, opportunities and plans. Alzheimer Dement. 11, 792-814 (2015).
14. Henrichs, I., Froesch, D., Wolf, A.S. & Teller WM. Impact of apolipoprotein E on Alzheimer's disease. Curr. Alzheimer Res. 10, 809-817 (2013).
15. Guerreiro, R. et al. TREM2 variants in Alzheimer's disease. N. Engl. J. Med. 368, 117-127 (2013).
16. Hooli, B.V. et al. The rare TREM2 R47H variant exerts only a modest effect on Alzheimer disease risk. Neurology 83, 1353-1358 (2014).
17. Nalls, M.A. et al. Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nat. Genet. 46, 989-993 (2014).
18. Satake, W. et al. Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet. 41, 1303-1307 (2009).
19. Simon-Sanchez, J. et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 41, 1308-1312 (2009).
20. Deleersnijder, A., Gerard, M., Debyser, Z. & Baekelandt, V. The remarkable conformational plasticity of alpha-synuclein: blessing or curse? Trends Mol. Med. 19, 368-377 (2013).
21. Vekrellis, K., Xilouri, M., Emmanouilidou, E., Rideout, H.J. & Stefanis, L. Pathological roles of α-synuclein in neurological disorders. Lancet Neurol. 10, 1015-1025 (2011).
22. Braak, H. et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging. 24, 197-211 (2003).
23. Li, J.Y. et al. Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat. Med. 14, 501-503 (2008).
24. Kordower, J.H., Chu, Y., Hauser, R.A., Freeman, T.B., Olanow, C.W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat. Med. 14, 504-506 (2008).
25. Hansen, C. et al. α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J. Clin. Invest. 121, 715-725 (2011).
26. Angot, E. et al. Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo. PLoS One 7, e39465 (2012).
27. Peelaerts, W. et al. α-Synuclein strains cause distinct synucleinopathies after local and systemic administration. Nature 522, 340-344 (2015).
28. Tran, H.T. et al. Á-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration. Cell Rep. 7, 2054-2065 (2014).
29. Muntane, G., Dalfo, E., Martinez, A. & Ferrer, I. Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies. Neuroscience 152, 913-923 (2008).
30. Duda, J.E. et al. Concurrence of alpha-synuclein and tau brain pathology in the Contursi kindred. Acta Neuropathol. 104, 7-11 (2002).
31. Poulopoulos, M., Levy, O.A. & Alcalay, R.N. The neuropathology of genetic Parkinson's disease. Mov. Disord. 27, 831-842 (2012).
32. Kumari, U. & Tan, E.K. LRRK2 in Parkinson's disease: genetic and clinical studies from patients. FEBS J. 276, 6455-6463 (2009).
33. Li, J.Q., Tan, L. & Yu, J.T. The role of the LRRK2 gene in Parkinsonism. Mol. Neurodegener. 9, 47 (2014).
34. Ross, O.A. et al. Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study. Lancet Neurol. 10, 898-908 (2011).
35. Greene, A.W. et al. Mitochondrial processing peptidase regulates PINK1 processing, import and Parkin recruitment. EMBO Rep. 13, 378-385 (2012).
36. Vives-Bauza, C. et al. PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc. Natl. Acad. Sci. U. S. A. 107, 378-383 (2010).
37. Kazlauskaite, A. et al. Parkin is activated by PINK1-dependent phosphorylation of ubiquitin at Ser65. Biochem. J. 460, 127-139 (2014).
38. Chan, N.C. et al. Broad activation of the ubiquitin-proteasome system by Parkin is critical for mitophagy. Hum. Mol. Genet. 20, 1726-1737 (2011).
39. Beavan, M.S. & Schapira, A.H.V. Glucocerebrosidase mutations and pathogenesis of PD. Ann. Med. 45, 511-521 (2013).
40. Mazzulli, J.R. et al. Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic lop in synucleopathies. Cell. 146, 1-16 (2011).
41. Yap, T.L. et al. α-Synuclein interacts with glucocerebrosidase providing a molecular link between Parkinson and Gaucher diseases. J. Biol. Chem. 286, 28080-28088 (2011).
42. Renton, A.E., Chio, A. & Traynor, B.J. State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci. 17, 17-23 (2014).
43. Andersen, P.M. & Al-Chalabi, A. Clinical genetics of amyotrophic lateral sclerosis: what do we really know? Nat. Rev. Neurol. 7, 603-615 (2011).
44. Bruijn, L.I. et al. Aggregation and motor neuron toxicity of an ALSlinked SOD1 mutant independent from wild-type SOD1. Science 281, 1851-1854 (1998).
45. Cooper-Knock, J., Shaw, P.J. & Kirby, J. The widening spectrum of C9ORF72-related disease; genotype/phenotype correlations and potential modifiers of clinical phenotype. Acta Neuropathol. 127, 333-345 (2014).
46. van Blitterswijk, M. et al. Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol. 12, 978-988 (2013).
47. DeJesus-Hernandez, M. et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9plinked FTD and ALS. Neuron. 72, 245-256 (2011).
48. Renton, A.E. et al. Ahexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 72, 257-268 (2011).
49. Lee, Y.B. et al. Hexanucleotide repeats in ALS/FTD formlengthdependent RNA foci, sequester RNA binding proteins, and are neurotoxic. Cell Rep. 5, 1178-1186 (2013).
50. Mori, K. et al. The C9ORF72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 339, 1335-1338 (2013).
51. Mann, D.M. et al. Dipeptide repeat proteins are present in the p62 positive inclusions in patients with frontotemporal lobar degeneration and motor neurone disease associated with expansions in C9ORF72. Acta Neuropathol. Commun. 1, 68 (2013).
52. Lee, B-Y. et al. Hexanucleotide repeats in ALS/FTD form length dependent RNA foci, sequester RNA binding protiens and are neurotoxic. Cell Rep. 5, 1178-1186 (2014).
53. Su, Z. et al. Discovery of a biomarker and lead small molecules to target r(GGGGCC) associated defects in C9FTD/ALS. Neuron. 83, 1-8 (2014).
54. Sareen, D. et al. Targeting RNA foci in iPSC-derived motor neurons from ALS patients with a C9ORF72 repeat expansion. Sci. Transl. Med. 5, 208ra149 (2013).
55. Cirulli, E.T. et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science 347, 1436-1441 (2015).
56. Freischmidt, A. et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-temporal dementia. Nat. Neurosci. 18, 631-636 (2015).
57. Joachim, C.L., Morris, J.H., Kosik, K.S. & Selkoe, D.J. Tau antisera recognize neurofibrillary tangles in a range of neurodegenerative disorders. Ann. Neurol. 22, 514-520 (1987).
58. Sreedharan, J. et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319, 1668-1672 (2008).
59. Bunker, J.M., Kamath, K., Wilson, L., Jordan, M.A. & Feinstein, S.C. FTDP-17 mutations compromise the ability of tau to regulate microtubule dynamics in cells. J. Biol. Chem. 281, 11856-11863 (2006).
60. Combs, B. & Gamblin, T.C. FTDP-17 tau mutations induce distinct effects on aggregation and microtubule interactions. Biochemistry 51, 8597-8607 (2012).
61. Arai, T. et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun. 351, 602-611 (2006).
62. Neumann, M., Kwong, L.K., Sampathu, D.M., Trojanowski, J.Q. & Lee, V.M. TDP-43 proteinopathy in frontotemporal lobar degeneration and amyotrophic lateral sclerosis: protein misfolding diseases without amyloidosis. Arch. Neurol. 64, 1388-1394 (2007).
63. Sreedharan, J. et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science 319, 1668-1672 (2008).
64. Borroni, B. et al. TARDBP Mutations in frontotemporal lobar degeneration: frequency, clinical features, and disease course. Rejuven. Res. 13, 509-517 (2010).
65. Lee, E.B., Lee, V.M. & Trojanowski, J.Q. Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat. Rev. Neurosci. 13, 38-50 (2012).
66. Buratti, E. & Baralle, F.E. The multiple roles of TDP-43 in pre-mRNA processing and gene expression regulation. RNA Biol. 7, 420-429 (2010).
67. King, O.D., Gitler, A.D. & Shorter, J. The tip of the iceberg: RNAbinding proteins with prion-like domains in neurodegenerative disease. Brain Res. 1462, 61-80 (2012).
68. Saini, A. & Chauhan, V.S. Delineation of the core aggregation sequences of TDP-43 C-terminal fragment. Chembiochem. 12, 2495-2501 (2011).
69. Sharp, A.H. et al. Widespread expression of Huntington's disease gene (IT15) protein product. Neuron. 14, 1065-1074 (1995).
70. Van Damme, P. et al. Expanded ATXN2 CAG repeat size in ALS identifies genetic overlap between ALS and SCA2. Neurology 76, 2066-2072 (2011).
71. Dyer, R.B. & McMurray, C.T. Mutant protein in Huntington disease is resistant to proteolysis in affected brain. Nat. Genet. 29, 270-278 (2001).
72. DiFiglia, M. et al. Therapeutic silencing of mutant Huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits. Proc. Natl. Acad. Sci. U. S. A. 104, 17204-17209 (2007).
73. Grondin, R. et al. Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum. Brain 135, 1197-1209 (2012).
74. Clabough, E.B.D. Huntington's disease: the past, present, and future search for disease modifiers. Yale J. Biol. Med. 86, 217-233 (2013).
75. Cook, D. et al. Lessons learned from the fate of Astra Zeneca's drug pipeline: a five-dimensional framework. Nat. Rev. Drug Discov. 13, 419-431 (2014).